BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• Drug Development

  Kos Pharmaceuticals Announces Overall Results For Two Phase III Trials Of Icatibant For The Treatment Of Hereditary Angioedema; Primary Endpoint Met In FAST-2 But Not Met In FAST-1

  September 22, 2006

   · 

  9 min read
• Business

  National Cancer Institute Awarded $111.6 Million Charles River Laboratories (Massachusetts) Contract; Charles River To Construct New Facility In Support Of Charles River And RMS Geographic Expansion

  September 22, 2006

   · 

  1 min read
• Policy

  Attorney’s Fees Granted In Takeda Pharmaceutical Co. Ltd.'s Patent Case On ACTOS(R)

  September 22, 2006

   · 

  2 min read
• Pharm Country

  Windhover Information Inc.'s FDA/CMS Summit For BioPharma Executives: Commercial Success In The Regulatory Environment; Government, Legal & Industry Experts To Offer Unique Insights; December 4-5, 2006

  September 22, 2006

   · 

  1 min read
• BioMidwest

  MonoSolRx LLC To Present At The UBS Warburg Global Life Sciences Conference

  September 22, 2006

   · 

  2 min read
• Business

  YM BioSciences Reports 2006 Year End Operational And Financial Results

  September 22, 2006

   · 

  16 min read
• Drug Development

  FDA Advisory Committee Strongly Endorses Use Of Bayer HealthCare’s Trasylol(R) In CABG Surgery Patients

  September 22, 2006

   · 

  3 min read
• Business

  PsychoGenics Inc. Expands Huntington Disease Research Collaboration With High Q Foundation And CHDI

  September 22, 2006

   · 

  3 min read
• BioForest

  Cardiome Pharma Corp. To Present At UBS Warburg Global Life Sciences Conference

  September 22, 2006

   · 

  4 min read
• Pharm Country

  Merck & Co., Inc. And Nicaragua Unveil New Rotavirus Vaccine Demonstration Project At Clinton Global Initiative; Merck & Co., Inc. Will Provide Free Rotavirus Vaccine For All Infants Born In Nicaragua Over The Next Three Years, A $75 Million Commitment

  September 22, 2006

   · 

  1 min read